Ligand Completes Acquisition of XOMA Royalty for ~$739 Million

Ligand Pharmaceuticals completed the acquisition of XOMA Royalty for ~$739 million, expanding its portfolio to over 200 royalty assets. The deal is expected to be immediately accretive and add exposure to major commercial products.